Business Context and Reporting Period
This Form 8-K Current Report is filed by NanoVibronix, Inc. (not Envue Medical, Inc.) for the event date of June 13, 2018. The filing reports on the results of the Company's 2018 Annual Meeting of Stockholders held on that date.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Voting Results
The following material matters were approved by stockholders at the Annual Meeting:
- Amendment to 2014 Long-Term Incentive Plan: Stockholders approved an amendment to increase the aggregate number of shares reserved for issuance by 750,000 shares (totaling 1,464,286 shares). Additionally, the maximum number of shares covering awards to executive officers in any calendar year was increased to 275,000.
- Election of Directors: Seven directors were elected to serve for a one-year term. All nominees received significant support, though Dr. Jona Zumeris received a notable number of withheld votes (250,883) compared to other nominees.
- Ratification of Auditors: Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document focuses exclusively on the procedural outcomes of the Annual Meeting.
Investor Verification Checklist
- Verify the exact number of shares reserved under the amended 2014 Long-Term Incentive Plan (1,464,286 shares).
- Review the voting results for Dr. Jona Zumeris, who received significantly more withheld votes than other director nominees.
- Confirm the ratification of Marcum LLP as the independent auditor for the fiscal year ending December 31, 2018.
- Note that this filing does not provide financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.